Addyi vs Vyleesi: What to Do When One Fails

How Addyi and Vyleesi Actually Work

These two drugs do not compete for the same receptor. Knowing that distinction is the first step in understanding why a failed trial of one leaves the door open for the other.

Flibanserin (Addyi): Central Serotonin and Dopamine Modulation

Flibanserin is a postsynaptic 5-HT1A agonist and 5-HT2A antagonist taken as a daily 100 mg oral tablet at bedtime [1]. By reducing serotonergic inhibition and increasing dopaminergic and noradrenergic tone in the prefrontal cortex, it attempts to rebalance the neurochemical ratio that governs sexual motivation. The drug requires consistent nightly dosing and typically takes four to eight weeks to produce measurable changes in desire [2].

The FDA drug label for flibanserin carries a boxed warning for severe hypotension and syncope when combined with alcohol, a warning that was the central reason the drug was rejected by FDA advisory committees twice before approval in 2015 [3].

Bremelanotide (Vyleesi): Melanocortin Receptor Activation

Bremelanotide is a cyclic heptapeptide melanocortin receptor agonist, primarily acting at MC3R and MC4R, administered as a 1.75 mg auto-injector subcutaneously in the abdomen or thigh approximately 45 minutes before anticipated sexual activity [4]. It does not require daily dosing. Because it works upstream of dopamine release rather than directly modulating serotonin reuptake sites, a woman who metabolized flibanserin adequately but did not respond clinically may still respond to bremelanotide [5].

The FDA prescribing information for bremelanotide notes that it is contraindicated in women with cardiovascular disease due to a transient increase in blood pressure averaging 2 mmHg systolic and lasting approximately 12 hours after each injection [6].

The Trial Data: What the Numbers Actually Show

Both drugs were approved on the basis of statistically significant, though modest, improvements in satisfying sexual events and desire scores. Understanding the actual effect sizes prevents unrealistic expectations and helps clinicians set honest benchmarks for treatment success or failure.

BEGONIA Trial: Flibanserin in Premenopausal HSDD

The BEGONIA trial (N=1,378) tested flibanserin 100 mg nightly versus placebo for 24 weeks in premenopausal women with generalized acquired HSDD [7]. Women on flibanserin reported a mean increase of 0.5 satisfying sexual events per month over placebo (P<0.001). The Female Sexual Function Index desire domain score improved by 1.0 point versus 0.7 points for placebo. Clinically meaningful response, defined as at least a moderate improvement on the Patient Global Impression of Change scale, occurred in 36% of flibanserin-treated women versus 22% receiving placebo [7].

Dizziness, somnolence, nausea, and fatigue were the most common adverse effects, each occurring in at least 10% of participants. The drug's 5-HT1A activity contributes directly to next-morning sedation, which is why the bedtime dosing requirement exists [2].

RECONNECT Trial: Bremelanotide in Premenopausal HSDD

The RECONNECT program (two identically designed phase 3 trials, combined N=1,267) evaluated bremelanotide 1.75 mg PRN versus placebo over 24 weeks in premenopausal women with HSDD or female sexual arousal disorder [8]. The primary outcomes were the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) score and the Female Sexual Function Index (FSFI) desire domain score.

Bremelanotide reduced the FSDS-DAO score by 12.4 points versus 9.6 points for placebo (P<0.001) and improved the FSFI desire domain score by 0.7 points versus 0.4 points (P<0.001) [8]. Nausea occurred in 40.4% of bremelanotide patients versus 1.3% of placebo patients and was the primary driver of discontinuation in the treatment arm.

Side-by-Side Effect Size Summary

| Endpoint | Flibanserin (BEGONIA) | Bremelanotide (RECONNECT) | |---|---|---| | Extra SSEs/month vs. Placebo | +0.5 | +0.5 | | FSFI desire domain improvement vs. Placebo | +0.3 points | +0.3 points | | Responder rate (PGIC "much/very much improved") | 36% vs. 22% placebo | Not reported as primary | | Most common adverse event | Dizziness (11%) | Nausea (40%) | | Discontinuation due to AEs | 13% | 17.9% |

The comparable SSE improvement figures reflect the fact that both drugs were approved on broadly similar effect sizes, which is why switching makes clinical sense when the first agent fails: the expected benefit from the second drug is not smaller than the expected benefit from the first.

Defining Treatment Failure: When Is It Time to Switch?

A common error is abandoning flibanserin after only two to four weeks. The drug's mechanism requires weeks of receptor adaptation. Switching too early wastes a genuine treatment opportunity.

Minimum Trial Duration for Flibanserin

The FDA labeling states that if no benefit is experienced after 8 weeks at 100 mg nightly, flibanserin should be discontinued [2]. HealthRX clinicians use this cutoff as the formal decision point. A woman who has taken the drug consistently for 8 weeks, has not skipped doses more than two nights per week, and reports no subjective improvement in desire or distress scores should be considered a flibanserin non-responder.

Structured measurement with a validated tool improves that judgment. The FSDS-DAO, freely available through the National Institutes of Health, takes under three minutes to complete and provides a numerical baseline for comparison at weeks 4 and 8 [9].

Minimum Trial Duration for Bremelanotide

Bremelanotide's PRN design complicates the non-responder definition. The RECONNECT protocol required use on at least one occasion per month for 24 weeks before outcomes were assessed [8]. For practical clinical purposes, a trial period of at least six to eight uses on separate occasions over eight to twelve weeks represents a reasonable minimum. A woman who has injected bremelanotide on six or more occasions and reports no change in desire or distress scores, or finds nausea or blood pressure elevations intolerable, meets criteria for non-response.

Partial Responders: A Third Category

Some women report improvement in desire scores without a meaningful change in distress, or vice versa. The ISSWSH Clinical Practice Guideline on HSDD recommends re-evaluating whether the primary complaint is desire deficit, distress, or relationship context before declaring pharmacologic failure [10]. A partial responder may benefit from adding sex therapy, addressing relationship stressors, or adjusting testosterone status before switching agents.

The Switch Protocol: From Addyi to Vyleesi

Flibanserin's half-life is approximately 11 hours, with all major metabolites cleared within 48 hours of the last dose [2]. No pharmacokinetic washout period beyond 48 hours is required before starting bremelanotide. The overlap risk is primarily theoretical CNS depression, not a pharmacodynamic interaction at the target receptor level.

Step 1: Stop Flibanserin and Confirm Washout

Take the last flibanserin tablet at bedtime. Wait 48 hours. No special taper is required; flibanserin does not cause physiologic dependence [2].

Step 2: Assess Cardiovascular Baseline Before Starting Bremelanotide

Bremelanotide is contraindicated in women with established cardiovascular disease, known hypertension exceeding 165/95 mmHg, or high cardiovascular risk [6]. Measure resting blood pressure at the prescribing visit. The American Heart Association defines stage 2 hypertension as systolic >140 mmHg or diastolic >90 mmHg, which should prompt blood pressure optimization before bremelanotide initiation [11].

Step 3: Teach Subcutaneous Injection Technique

Bremelanotide comes as a single-dose auto-injector. The injection site should rotate between the abdomen (avoiding a 2-inch radius around the navel) and the outer thigh. Patients should be counseled to inject 45 minutes before sexual activity, not immediately before, to allow for peak plasma concentration [4].

Step 4: Manage Nausea Proactively

Given the 40% nausea rate in RECONNECT, prescribing a PRN antiemetic at the time of bremelanotide initiation is a practical step most major telehealth guidelines now recommend. Ondansetron 4 mg orally 30 minutes before each injection is a common choice, though direct evidence from a randomized trial for this combination is not yet published. Nausea typically peaks 30 to 60 minutes post-injection and resolves within 2 to 4 hours [8].

Step 5: Set a Structured Re-Evaluation Date

Schedule a follow-up at 8 to 12 weeks with repeat FSDS-DAO and FSFI desire domain scoring. If scores have not improved by at least the minimal clinically important difference (1.0 point on the FSFI desire domain per Rosen et al.), document treatment failure and discuss non-pharmacologic options [12].

The Switch Protocol: From Vyleesi to Addyi

Bremelanotide's half-life is approximately 2.7 hours, with elimination essentially complete within 24 hours of the last injection [4]. No washout is needed beyond 24 hours before starting flibanserin.

Key Counseling Points Unique to Flibanserin

The alcohol interaction is non-negotiable and permanent for as long as the woman takes flibanserin. The FDA Risk Evaluation and Mitigation Strategy (REMS) program for flibanserin requires that prescribers enroll and that patients acknowledge the alcohol warning in writing [3]. This is not a soft advisory. A single standard drink taken within two hours of a flibanserin dose can cause symptomatic hypotension and syncope [2].

Women switching from bremelanotide to flibanserin who drink alcohol socially should have a direct, detailed conversation about this before the first prescription is written. Some women find the daily dosing schedule and alcohol restriction more burdensome than the nausea associated with bremelanotide, and they may prefer to return to the injectable option or pursue non-pharmacologic care.

CNS Medication Interactions to Screen Before Starting Flibanserin

Flibanserin is a CYP3A4 substrate. Co-administration with moderate or strong CYP3A4 inhibitors, including fluconazole, ketoconazole, clarithromycin, and combined hormonal contraceptives containing certain progestins, can raise flibanserin plasma levels substantially [2]. The FDA label specifies that fluconazole increases flibanserin exposure by approximately 7-fold [2]. Screen the full medication list before prescribing.

What to Do When Both Drugs Fail

Neither drug works for every woman. When both a full 8-week flibanserin trial and a 6-to-8-use bremelanotide trial produce no clinically meaningful improvement, the next steps involve broadening the diagnostic picture rather than cycling through the same two agents again.

Rule Out Underlying Hormonal Causes

Low testosterone is not an FDA-approved indication for any drug in women, but the Endocrine Society Clinical Practice Guideline on Androgen Therapy in Women acknowledges that testosterone replacement may benefit postmenopausal women with HSDD who do not respond to standard care [13]. Total testosterone and free androgen index testing is reasonable. The same guideline does not recommend testosterone for premenopausal women outside of research settings, so referral to an endocrinologist or gynecologist with HSDD subspecialty training is appropriate in that group.

Evaluate for Depression, Anxiety, and Relationship Context

The DSM-5 diagnostic criteria for HSDD require that the disorder not be fully explained by a non-sexual mental health disorder, a relationship problem, or medication effects [14]. Antidepressants, including SSRIs and SNRIs, are among the most common iatrogenic causes of decreased desire. If a woman has been started on an SSRI since her HSDD diagnosis, that alone may be sufficient to explain pharmacologic non-response to both flibanserin and bremelanotide.

Sex therapy, specifically sensate focus and cognitive behavioral approaches, has evidence-based support in systematic reviews and represents the recommended first-line or concurrent treatment in most international guidelines [10].

Special Populations: Perimenopausal and Postmenopausal Women

Both flibanserin and bremelanotide carry FDA approval only for premenopausal women. Use in perimenopausal or postmenopausal women is off-label. The Menopause Society (formerly NAMS) Position Statement on Sexual Function recommends that estrogen deficiency be corrected with local or systemic hormone therapy before attributing desire problems to primary HSDD in menopausal women [15]. Prescribing either FDA-approved HSDD drug to a postmenopausal woman without first addressing genitourinary syndrome of menopause is a clinical sequencing error.

Ospemifene, local estrogen, and the DHEA intravaginal preparation prasterone address pain and arousal dysfunction rather than central desire, but resolving those barriers sometimes restores desire without any additional pharmacotherapy.

Drug Interactions, Contraindications, and Safety Flags at a Glance

| Factor | Flibanserin (Addyi) | Bremelanotide (Vyleesi) | |---|---|---| | Absolute contraindication | Alcohol use; strong CYP3A4 inhibitors; hepatic impairment | Cardiovascular disease; uncontrolled hypertension | | REMS required | Yes | No | | Pregnancy | Avoid (no data; animal reproduction studies show harm) | Avoid (no data; discontinue before conception) | | Breastfeeding | Unknown excretion; avoid | Unknown excretion; avoid | | Drug interaction risk | High (CYP3A4, alcohol, CNS depressants) | Low (no significant CYP interactions) | | Cost without insurance | ~$800-$900/month | ~$800-$1,000/month per auto-injector package |

HealthRX Clinical Decision Framework: Addyi vs Vyleesi When One Fails

The following decision tree is used by HealthRX-affiliated clinicians when a patient with diagnosed HSDD has not responded to the first FDA-approved agent.

Step A. Confirm adherence. Has the patient taken flibanserin at least 5 of 7 nights for 8 consecutive weeks, or has the patient used bremelanotide on at least 6 separate occasions? If no, optimize adherence before declaring failure.

Step B. Confirm diagnosis. Has depression, SSRI use, relationship conflict, or genitourinary syndrome been re-evaluated since the initial visit? If new confounders have appeared, address them first.

Step C. Assess contraindications for the second agent. For bremelanotide: measure blood pressure. For flibanserin: confirm alcohol use habits and review all CYP3A4 comedications.

Step D. Prescribe the second agent with structured outcome tracking. Set a formal re-evaluation date at 8 to 12 weeks with repeat validated scoring.

Step E. If both agents fail, refer to a clinician with subspecialty training in female sexual medicine. Consider testosterone testing, sex therapy referral, and re-evaluation of the underlying diagnosis per ISSWSH guidelines [10].